Real-world evidence continues to grow on the impact and effectiveness of the Bexsero MenB vaccine

05 May 2021
Real-world evidence continues to grow on the impact and effectiveness of the Bexsero MenB vaccine
 A new paper has been published in the Journal of Infection describing the most recently available effectiveness and impact data for the MenB vaccine Bexsero.
 
With data now available from seven countries, there is a consistent and growing body of real-world data supporting the effectiveness of Bexsero in preventing MenB disease in vaccinated individuals, and in reducing the disease incidence in populations.
 
At least two doses of Bexsero were found to reduce MenB disease by between 50-100% while estimates of vaccine effectiveness in fully vaccinated cohorts ranged from 59% to 100%.
 
The safety profile of the vaccine used in real-world settings also remains consistent with that established in clinical trials, and no safety concerns have been raised in post-marketing surveillance.
 
Terms used in the study and their meanings:

  • 'Vaccine effectiveness': the risk of MenB diseases in vaccinated individuals compared to unvaccinated individuals
  • 'Vaccine impact': reduction in MenB disease in the population over time in vaccine eligible individuals, regardless of vaccination status
We fund research into the prevention, detection and treatment of meningitis and sepsis
Current research programme - Investigating whether a single dose of the MenB vaccine is enough to boost teenagers' immunity gained from infant MenB vaccination
Vaccine hesitancy is one of the biggest threats to global health. But why does it happen?
Give researchers the clues to help defeat meningitis
Give researchers the clues to help defeat meningitis
£160/€190/$214 decodes the genetic information in a sample of meningococcal bacteria. This information helps us to track new forms of meningitis and campaign to introduce new vaccines.
Media contact
Holly Edwards - Communications Manager
Tel: 07875 498 047
Share this